ZAS Corporation is proud to announce the successful launch of Polymyxin B, a groundbreaking antibiotic from our Critical Care division. This potent medication is specifically designed to target and treat serious infections caused by multidrug-resistant gram-negative bacteria, a major concern in healthcare today.

The launch event was marked by a comprehensive Training Session for our Critical Care team, ensuring they are well-equipped with the necessary knowledge and skills to utilize this powerful antibiotic effectively. The training was followed by an exam to assess their understanding, culminating in a prize ceremony to honor the top three achievers for their outstanding performance.

We believe Polymyxin B will be a game-changer in the fight against multidrug-resistant infections, significantly enhancing healthcare outcomes in Bangladesh.